Several lines of investigation have revealed the apparent interplay between the immune
system of the host and many conventional, “standard-of-care” anticancer therapies, including …

… Disclosures: Vincenzo Formica reports personal fees from and consulting or advisory
role with Amgen, Servier, Merck, Sanofi; Chiara Cremolini reports personal fees from Roche, …

Neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) ratios might represent a yet
unrecognized risk factor for venous thromboembolism (VTE) in cancer out‐patients receiving …

PURPOSE To verify whether the intensification of the upfront chemotherapy backbone with
a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (…

Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed
death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and …

In the last decade a growing body of epidemiological and clinical data has emerged to support
the concept that longstanding inflammation potentiates or promotes tumor development, …

The SARS-CoV-2 pandemic has dramatically increased the workload for health systems and
a consequent need to optimise resources has arisen, including the selection of patients for …

Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …

Background. Based on the hypothesis that impaired glucose metabolism might be associated
with survival outcomes independently of overt diabetes, we sought to investigate the …

Background: Signaling pathways triggered by increased thrombin or plasminogen activator
inhibitor-1 (PAI-1) expression drastically alter the tumor microenvironment, contributing to an …